Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus 2) infection: case report and review

Vestibular neuritis is a disorder selectively affecting the vestibular portion of the eighth cranial nerve generally considered to be inflammatory in nature. There have been no reports of severe acute respiratory syndrome coronavirus 2 causing vestibular neuritis. We present the case of a 42-year-old Caucasian male physician, providing care to COVID-19 patients, with no significant past medical history, who developed acute vestibular neuritis, 2 weeks following a mild respiratory illness, later diagnosed as COVID-19. Physicians should keep severe acute respiratory syndrome coronavirus 2 high on the list as a possible etiology when suspecting vestibular neuritis, given the extent and implications of the current pandemic and the high contagiousness potential.

Download Full-text

P1574EFFECTS OF BRAZILIAN GREEN PROPOLIS EXTRACT (EPP-AF) ON INFLAMMATION IN HEMODIALYSIS PATIENTS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfaa142.p1574 ◽

2020 ◽

Vol 35 (Supplement_3) ◽

Author(s):

Marcelo Silveira ◽

Flavio Teles ◽

Erica Melo ◽

Valeria Borges ◽

Filipe Miranda ◽

...

Keyword(s):

Control Period ◽

Prospective Trial ◽

Hemodialysis Patients ◽

Intermittent Hemodialysis ◽

Plant Materials ◽

Propolis Extract ◽

End Point ◽

Number Of Patients ◽

The Impact ◽

Brazilian Green Propolis

Abstract Background and Aims End-stage chronic kidney disease is associated with the condition of chronic inflammation, impacting increased cardiovascular mortality in this specific population. Patients on hemodialysis are known to be predisposed to several factors that predispose to inflammation: dialysis membranes, central venous catheters, oxidative stress, fluid overload, sodium overload, uraemic toxins. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, and anti-oxidant properties. The aim of this study was to evaluate the impact of Brazilian green propolis extract on inflammation in hemodialysis patients. Here we present preliminary results of the trial NCT04072341. Method We performed a prospective trial, open-label 9-week crossover study examining the effect of Brazilian green propolis (250mg/day, in capsules) on inflammation in hemodialysis patients. We included patients over 18 years, under intermittent hemodialysis (thrice per week), on hemodialysis for at least 1 month and until now 37 patients were included. We excluded pregnant women, cancer carried and patients who developed infection or underwent any surgical procedure during the study period. Each period was 4 weeks in duration with a 1-week washout period in between. The primary end point was change in serum level of high-sensitivity c-reactive protein (HsCRP). Secondary end point evaluated the safety of propolis use in hemodialysis patients. Results Their mean age was 58.6 ± 15.2 years (mean ± SD), and 22 (59.4%) were men. The proportion of patients with hypertension was 14 (37.8%) and diabetes was 9 (24.3%). The number of patients using arteriovenous fistula were 26 (70.2%). The HsCRP presented (mean ± SE) 5.31 ± 1.02 mg/L at baseline, 4.26 ± 0.76 mg/L after propolis period and 4.56 ± 1.32 mg/L in control period, p = 0.0042. Safety parameters were analyzed such as amylase, aspartate aminotransferase (AST) and creatine phosphokinase (CPK); there was no difference between them before and after the use of propolis. None of the participants reported any adverse effects or allergic reactions during the treatment. Conclusion Patients on hemodialysis have an increased inflammatory state. For the best of our knowledge it was the first clinical trial who demonstrated the safety of propolis in hemodialysis patients. Brazilian green propolis demonstrated a tendency to reduce inflammation in these patients.

Download Full-text

Acute Tubulointerstitial Nephritis in a Patient on Anti-Programmed Death-Ligand 1 Triggered by COVID-19: A Case Report

Canadian Journal of Kidney Health and Disease ◽

10.1177/20543581211014745 ◽

2021 ◽

Vol 8 ◽

pp. 205435812110147

Author(s):

Dimitry Buyansky ◽

Catherine Fallaha ◽

François Gougeon ◽

Marie-Noëlle Pépin ◽

Jean-François Cailhier ◽

...

Keyword(s):

Case Report ◽

Severe Acute Respiratory Syndrome ◽

Tubulointerstitial Nephritis ◽

Checkpoint Inhibitor ◽

Checkpoint Inhibitors ◽

High Dose ◽

Programmed Death Ligand 1 ◽

Acute Tubulointerstitial Nephritis ◽

Programmed Death ◽

Kidney Involvement

Rationale: Immune checkpoint inhibitors are monoclonal antibodies used in the treatment of various types of cancers. The downside of using such molecules is the potential risk of developing immune-related adverse events. Factors that trigger these autoimmune side effects are yet to be elucidated. Although any organ can potentially be affected, kidney involvement is usually rare. In this case report, we describe the first known instance of a patient being treated with an inhibitor of programmed death-ligand 1 (anti-PD-L1, a checkpoint inhibitor) who develops acute tubulointerstitial nephritis after contracting the severe acute respiratory syndrome coronavirus 2. Presenting concerns of the patient: A 62-year-old patient, on immunotherapy treatment for stage 4 squamous cell carcinoma, presents to the emergency department with symptoms of lower respiratory tract infection. Severe acute kidney injury is discovered with electrolyte imbalances requiring urgent dialysis initiation. Further testing reveals that the patient has contracted the severe acute respiratory syndrome coronavirus 2. Diagnosis: A kidney biopsy was performed and was compatible with acute tubulointerstitial nephritis. Interventions: The patient was treated with high dose corticosteroid therapy followed by progressive tapering. Outcomes: Rapid and sustained normalization of kidney function was achieved after completion of the steroid course. Novel findings: We hypothesize that the viral infection along with checkpoint inhibitor use has created a proinflammatory environment which led to a loss of self-tolerance to renal parenchyma. Viruses may play a more important role in the pathogenesis of autoimmunity in this patient population than was previously thought.

Download Full-text

Covid-19 And Sudden Death with Pulmonary Manifestations- A Case Report

International Journal of Forensic Research ◽

10.33140/ijfr.02.01.01 ◽

2021 ◽

Vol 2 (1) ◽

Keyword(s):

Case Report ◽

Severe Acute Respiratory Syndrome ◽

Sudden Death ◽

Common Cold ◽

Respiratory Symptoms ◽

Transmission Dynamics ◽

Pulmonary Manifestations ◽

The Family ◽

The Common ◽

Virus Strains

Covid 19 being a pandemic has uniformly and bizarrely affected the globe in a most unpredictable manner. So it becomes very important to unravel the transmission dynamics and the effect of the virus which has made it a deadly virus so far. Covid 19 is a member of coronavirus family, which also includes the SARS virus (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Symptoms) virus. The family of Coronavirus includes virus strains that the common cold and flu are caused [1].

Download Full-text

Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives

Future Medicinal Chemistry ◽

10.4155/fmc-2020-0204 ◽

2020 ◽

Vol 12 (19) ◽

pp. 1743-1757

Author(s):

Anna Pawełczyk ◽

Lucjusz Zaprutko

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Antiviral Activity ◽

Small Molecules ◽

Computational Chemistry ◽

Structural Modification ◽

Antiviral Agents ◽

Complex Molecules ◽

Active Complex ◽

Novel Virus ◽

Effective Drugs

At the end of 2019, a novel virus causing severe acute respiratory syndrome to spread globally. There are currently no effective drugs targeting SARS-CoV-2. In this study, based on the analysis of numerous references and selected methods of computational chemistry, the strategy of integrative structural modification of small molecules with antiviral activity into potential active complex molecules has been presented. Proposed molecules have been designed based on the structure of triterpene oleanolic acid and complemented by structures characteristic of selected anti-COVID therapy assisted drugs. Their pharmaceutical molecular parameters and the preliminary bioactivity were calculated and predicted. The results of the above analyses show that among the designed complex substances there are potential antiviral agents directed mainly on SARS-CoV-2.

Download Full-text

Prolonged severe acute respiratory syndrome of Corona Virus-2 positive with polymerase chain reaction: A case report

Jurnal kedokteran dan kesehatan Indonesia ◽

10.20885/jkki.vol11.iss3.art12 ◽

2020 ◽

Vol 11 (3) ◽

pp. 295-301

Author(s):

Linda Rosita ◽

Rahma Yuantari ◽

Budi Mulyono ◽

Umi Solekhah Intansari ◽

Ingesti Bilkis Zulfatina

Keyword(s):

Polymerase Chain Reaction ◽

Case Report ◽

Severe Acute Respiratory Syndrome ◽

Chain Reaction ◽

Corona Virus ◽

Polymerase Chain

Download Full-text

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

10.1101/2020.12.30.424862 ◽

2020 ◽

Author(s):

Scott B. Biering ◽

Erik Van Dis ◽

Eddie Wehri ◽

Livia H. Yamashiro ◽

Xammy Nguyenla ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Combination Therapy ◽

Global Health ◽

Antiviral Activity ◽

Drug Repurposing ◽

Rapid Identification ◽

Screening Strategy ◽

Combination Therapies ◽

Pulmonary Epithelial Cells ◽

Compound Screening

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has emerged as a major global health threat. The COVID-19 pandemic has resulted in over 80 million cases and 1.7 million deaths to date while the number of cases continues to rise. With limited therapeutic options, the identification of safe and effective therapeutics is urgently needed. The repurposing of known clinical compounds holds the potential for rapid identification of drugs effective against SARS-CoV-2. Here we utilized a library of FDA-approved and well-studied preclinical and clinical compounds to screen for antivirals against SARS-CoV-2 in human pulmonary epithelial cells. We identified 13 compounds that exhibit potent antiviral activity across multiple orthogonal assays. Hits include known antivirals, compounds with anti-inflammatory activity, and compounds targeting host pathways such as kinases and proteases critical for SARS-CoV-2 replication. We identified seven compounds not previously reported to have activity against SARS-CoV-2, including B02, a human RAD51 inhibitor. We further demonstrated that B02 exhibits synergy with remdesivir, the only antiviral approved by the FDA to treat COVID-19, highlighting the potential for combination therapy. Taken together, our comparative compound screening strategy highlights the potential of drug repurposing screens to identify novel starting points for development of effective antiviral mono- or combination therapies to treat COVID-19.

Download Full-text

Use of lung ultrasound for diagnosis and monitoring of coronavirus disease 2019 pneumonia: A case report

SAGE Open Medical Case Reports ◽

10.1177/2050313x20958915 ◽

2020 ◽

Vol 8 ◽

pp. 2050313X2095891

Author(s):

Debo Yun ◽

Yan Cui ◽

Yuan Geng ◽

Yujiao Yang

Keyword(s):

Case Report ◽

Severe Acute Respiratory Syndrome ◽

Early Diagnosis ◽

Lung Ultrasound ◽

Nasopharyngeal Swab ◽

Ultrasound Images ◽

Healthcare Settings ◽

Pleural Line ◽

Ultrasound Findings ◽

Spread Of Infection

Knowledge of lung ultrasound characteristics of coronavirus disease 2019 pneumonia might be useful for early diagnosis and clinical monitoring of patients, and lung ultrasound can help to control the spread of infection in healthcare settings. In this case report, a 36-year-old man with severe acute respiratory syndrome coronavirus 2 infection was diagnosed by reverse transcription-polymerase chain reaction testing of a nasopharyngeal swab. The lung ultrasound findings for this patient were the interstitial-alveolar damage showing bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts. When the patient recovered from the severe acute respiratory syndrome coronavirus 2 infection, lung ultrasound images showed a normal pleural line with A-lines regularly reverberating. Performing lung ultrasound at the bedside minimizes the need to move the patient, thus reducing the risk of spreading infection among healthcare staff. Lung ultrasound is useful for early diagnosis and evaluation of the severity of coronavirus disease 2019 pneumonia and for monitoring its progress over the course of the disease.

Download Full-text